Stéphanie Solier

Dr. Stéphanie Solier

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
WBWilliam M. Bonner
William M. Bonner
CRChristophe E. Redon
Christophe E. Redon
JDJennifer S. Dickey
Jennifer S. Dickey
ANAsako J. Nakamura
Asako J. Nakamura
OSOlga A. Sedelnikova
Olga A. Sedelnikova
YPYves Pommier
Yves Pommier

7 May 2025 in Nature
Verified
Journal Article
Open access
PDF file
TCTatiana Cañeque
Tatiana Cañeque
LBLeeroy Baron
Leeroy Baron
SMSebastian Müller
Sebastian Müller
ACAlanis Carmona
Alanis Carmona
LCLudovic Colombeau
Ludovic Colombeau
RRRaphaël Rodriguez
Raphaël Rodriguez
Iron catalyses the oxidation of lipids in biological membranes and promotes a form of cell death called ferroptosis1. Defining where this chemistry occurs in the cell can inform the design of drugs capable of inducing or inhibiting ferroptosis in various disease-relevant settings. Genetic approaches have revealed suppressors of ferroptosis2,3,4; by contrast, small molecules can provide spatiotemporal control of the chemistry at work5. Here we show that the ferroptosis inhibitor liproxstatin-1 exerts cytoprotective effects by inactivating iron in lysosomes. We also show that the ferroptosis inducer RSL3 initiates membrane lipid oxidation in lysosomes. We designed a small-molecule activator of lysosomal iron—fentomycin-1—to induce the oxidative degradation of phospholipids and ultimately ferroptosis. Fentomycin-1 is able to kill iron-rich CD44high primary sarcoma and pancreatic ductal adenocarcinoma cells, which can promote metastasis and fuel drug tolerance. In such cells, iron regulates cell adaptation6,7 while conferring vulnerability to ferroptosis8,9. Sarcoma cells exposed to sublethal doses of fentomycin-1 acquire a ferroptosis-resistant cell state characterized by the downregulation of mesenchymal markers and the activation of a membrane-damage response. This phospholipid degrader can eradicate drug-tolerant persister cancer cells in vitro and reduces intranodal tumour growth in a mouse model of breast cancer metastasis. Together, these results show that control of iron reactivity confers therapeutic benefits, establish lysosomal iron as a druggable target and highlight the value of targeting cell states10.

26 June 2009 in EMBO Reports
Verified
Journal Article
Open access
PDF file
OSOlivier Sordet
Olivier Sordet
CRChristophe E Redon
Christophe E Redon
JGJosée Guirouilh‐Barbat
Josée Guirouilh‐Barbat
SSSusan Smith
Susan Smith
SSStéphanie Solier
Stéphanie Solier
YPYves Pommier
Yves Pommier
Ataxia telangiectasia mutated (ATM), the deficiency of which causes a severe neurodegenerative disease, is a crucial mediator for the DNA damage response (DDR). As neurons have high rates of transcription that require topoisomerase I (TOP1), we investigated whether TOP1 cleavage complexes (TOP1cc)—which are potent transcription‐blocking lesions—also produce transcription‐dependent DNA double‐strand breaks (DSBs) with ATM activation. We show the induction of DSBs and DDR activation in post‐mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, γ‐H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1). The DSB–ATM–DDR pathway was suppressed by inhibiting transcription and γ‐H2AX signals were reduced by RNase H1 transfection, which removes transcription‐mediated R‐loops. Thus, we propose that Top1cc produce transcription arrests with R‐loop formation and generate DSBs that activate ATM in post‐mitotic cells.

24 February 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJane Merlevede
Jane Merlevede
NDNathalie Droin
Nathalie Droin
TQTingting Qin
Tingting Qin
KMKristen Meldi
Kristen Meldi
KYKenichi Yoshida
Kenichi Yoshida
ESEric Solary
Eric Solary
The cytidine analogues azacytidine and 5-aza-2’-deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It remains unclear whether the response to these hypomethylating agents results from a cytotoxic or an epigenetic effect. In this study, we address this question in chronic myelomonocytic leukaemia. We describe a comprehensive analysis of the mutational landscape of these tumours, combining whole-exome and whole-genome sequencing. We identify an average of 14±5 somatic mutations in coding sequences of sorted monocyte DNA and the signatures of three mutational processes. Serial sequencing demonstrates that the response to hypomethylating agents is associated with changes in DNA methylation and gene expression, without any decrease in the mutation allele burden, nor prevention of new genetic alteration occurence. Our findings indicate that cytosine analogues restore a balanced haematopoiesis without decreasing the size of the mutated clone, arguing for a predominantly epigenetic effect.

15 June 2009 in Cell Cycle
Verified
Journal Article
Open access
SSStéphanie Solier
Stéphanie Solier
YPYves Pommier
Yves Pommier
We recently showed that histone H2AX phosphorylated on serine 139 (γ-H2AX), a hallmark of DNA damage response (DDR), also forms early during apoptosis induced by death receptor activation. Here, we...

22 January 2014 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
SSStéphanie Solier
Stéphanie Solier
YPYves Pommier
Yves Pommier